Mouse PLAT Protein

Plasminogen activator, tissue Protein Datasheet

PLAT Protein Product Information

• Synonym: PLAT
• Protein Construction: A DNA sequence encoding the mouse PLAT (P11214) (Ile309-Gln559) was was expressed with the fused Fc region of human IgG1 at the N-terminus.
• Source: Mouse
• Expression Host: Human Cells

PLAT Protein QC Testing

• Purity: > 80 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu
• Molecular Mass: The recombinant mouse PLAT/Fc comprises 511 amino acids and has a predicted molecular mass of 56.4 kDa. The apparent molecular mass of the protein is approximately 57kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Formulation: Lyophilized from sterile PBS,pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: PLAT protein

PLAT Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

PLAT Protein Description

PLAT, also known as plasminogen activator and tissue plasminogen activator, is a member of the peptidase S1 family. It is a heterodimer of chain A and chain B held by a disulfide bond. PLAT contains 1 EGF-like domain, 1 fibronectin type-I domain and 2 kringle domains. It is synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk. PLAT forms heterodimer with SERPINA5. It binds to fibrin with high affinity. It also binds to annexin A2, cytokeratin-8, fibronectin and laminin. Increased activity of plasminogen activator results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of plasminogen activator results in hypofibrinolysis that can lead to thrombosis or embolism.

References

1. Zhuo M. et al., 2000, J eurosci. 20 (2): 542-9.
2. Ichinose A. et al., 1986, J Clin Invest. 78 (1): 163-9.
3. Mateen FJ. et al., 2009, Mayo Clin Proceedings. 84 (4): 384-8.